← All Spyglass Pharma, INC filings

Spyglass Pharma, INC 8-K filings

Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.

NASDAQ
SGP
Spyglass Pharma, INC
8-K: SpyGlass Pharma Q1 2026 Results: BIM-IOL Trial Data Strong
SpyGlass Pharma reported Q1 2026 financial results, highlighting positive Phase 1/2 data for its BIM-IOL System and strong cash reserves.
NASDAQ
SGP
Spyglass Pharma, INC
8-K: SpyGlass Pharma IPO Fuels Glaucoma Drug Development
SpyGlass Pharma reports positive Phase 1/2 BIM-IOL data, successful $172.5M IPO, and extended cash runway through 2028, despite increased net losses in 2025.
NASDAQ
SGP
Spyglass Pharma, INC
8-K: SpyGlass Pharma Approves 2025 Executive Bonuses
SpyGlass Pharma's Compensation Committee approved performance cash bonuses for its Named Executive Officers for Fiscal Year 2025, updating previously undisclosed compensation figures.
NASDAQ
SGP
Spyglass Pharma, INC
8-K: SpyGlass Pharma Closes $172.5M IPO, Appoints New Director
SpyGlass Pharma, Inc. announced the successful closing of its initial public offering, raising $172.5 million, and the appointment of Habib Dable to its board of directors.